Clinical Trial Update: Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MT-3921 for acute traumatic cervical spinal cord injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• MT-3921

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: Spinal Cord Injury | Phase 2 | Status: COMPLETED